Osaka University to launch world’s first iPS clinical study of heart disease treatment
July 22, 2017
OSAKA- A research group led by Yoshiki Sawa, professor at Osaka University, has filed with a committee of the university for the world's first clinical study on a heart disease treatment using iPS cells.
If the project is approved by the committee, the group will file with the government and launch the clinical study in the first half of 2018.
The study will cover three ischemic cardiomyopathy sufferers aged 18 to 75. Heart muscle cell sheets produced from induced pluripotent stem cells will be transplanted into them and their condition will be observed.
Sawa and colleagues will use iPS cells stockpiled at Kyoto University's Center for iPS Cell Research and Application after being produced from mature cells of people who have a special immunological type that is less likely to cause rejection responses.
They will have the iPS cells develop into cardiomyocytes, make 0.1-millimeter-thick 5-centimeter-diameter sheets of the muscle cells and attach the sheets to the hearts of the patients.
After the sheet transplants, the team will specifically see if no cancer is developed and the hearts function better. The application for the clinical study was filed on Thursday. (Jiji Press)
Latest Videos
- GEORGE SOROS BLASTED THE U S FOR SUPPORTING ISRAEL ON NOT WORKING WITH HAMAS
- WIKILEAKS REVELATIONS SHOW U S ‘IGNORED’ TORTURE FROM THE WAR IN IRAQ
- THE ROOTS OF THE ISRAEL PALESTINE CONFLICT
- TUCKER CARLSON QUESTIONS U.S SUPPORT FOR ISRAEL WAR
- RFK Jr TO RUN FOR PRESIDENT AS INDEPENDENT, DECLARING INDEPENDENCE FROM THE TWO POLITICAL PARTIES
- JAPANESE VIROLOGIST SAYS OMICRON MAY HAVE BEEN MANUFACTURED
- JAPANESE VIEW & FILIPINO BEAUTY
